Artelo Biosciences (ARTL) announced that the European Patent Office has issued a Notice of Allowance for Artelo’s European patent application No. 21827629.3. The application covers the intended commercial formulation of ART27.13, the Company’s peripherally selective cannabinoid agonist currently under evaluation in the Phase 2 CAReS trial for the treatment of cancer-related anorexia. The allowed claims protect compositions of ART27.13 dispersed in polyethylene glycol, including the Company’s intended commercial formulation. This development marks a major milestone in Artelo’s global intellectual property strategy and positions the Company for long-term value creation.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTL:
- Artelo Biosciences Partners with ABK Labs for Strategic Growth
- Artelo Biosciences announces private placement to initiate Solana treasury
- Artelo Biosciences receives MHRA guidance for Phase 1 trial of ART12.11
- Artelo Biosciences Announces At-The-Market Offering Agreement
- Artelo Biosciences files to sell 920K shares of common stock for holders